drugset / Trial / NCT05053750
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 0
Active not recruiting
14 enrolled
M.D. Anderson Cancer Center
Gateway for Cancer Research · collabNational Cancer Institute (NCI) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.
Timeline
- Start
- 2021-12-14
- Primary completion
- 2027-02-02
- Completion
- 2027-02-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | — | Oral |
| Background | Bevacizumab | Monoclonal antibody | — | Oral |
| Background | Paclitaxel | Small molecule | — | Oral |